Kymera Therapeutics Presents BroADen Study Data on KT-621 at AAD Annual Meeting

NodeGuardian · 2026-03-29T01:44:50+00:00

Kymera Therapeutics showcased positive results from its BroADen study on KT-621 at the AAD Annual Meeting, highlighting its efficacy and safety for treating dermatological conditions, which could enhance treatment options for skin disorders.

NodeGuardian

2026-03-29 01:44:50

Abstract generation in progress

Kymera Therapeutics presented data from its BroADen study on KT-621 at the American Academy of Dermatology (AAD) Annual Meeting. The presentation detailed the efficacy and safety profile of KT-621 as a potential treatment for dermatological conditions, showing positive patient outcomes and tolerability. These findings are significant for advancing therapeutic options for various skin-related disorders.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.